Cargando…

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions

BACKGROUND: Patients with malignant mesothelioma have a poor prognosis and only 40% respond to first line treatment; a combination of pemetrexed and cisplatin or carboplatin. We used primary malignant mesothelioma cells and an ex vivo chemosensitivity assay with future purpose to predict best choice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szulkin, Adam, Ötvös, Rita, Hillerdal, Carl-Olof, Celep, Aytekin, Yousef-Fadhel, Eviane, Skribek, Henriette, Hjerpe, Anders, Székely, László, Dobra, Katalin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190467/ https://www.ncbi.nlm.nih.gov/pubmed/25253633 http://dx.doi.org/10.1186/1471-2407-14-709

Ejemplares similares

Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma
por: Ötvös, Rita, et al.
Publicado: (2015)

Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
por: Hillerdal, Carl-Olof, et al.
Publicado: (2017)

Multiplex Soluble Biomarker Analysis from Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2020)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Proteome Screening of Pleural Effusions Identifies Galectin 1 as a Diagnostic Biomarker and Highlights Several Prognostic Biomarkers for Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2014)

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy
por: Szulkin, Adam, et al.
Publicado: (2013)

Diagnostic and Prognostic Utility of the Extracellular Vesicles Subpopulations Present in Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2021)

Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication
por: Szatmári, Tünde, et al.
Publicado: (2015)

Inhibitors of cytoskeletal dynamics in malignant mesothelioma
por: Reis, Katarina, et al.
Publicado: (2020)

Cytoskeletal Organization Correlates to Motility and Invasiveness of Malignant Mesothelioma Cells
por: Keller, Maureen, et al.
Publicado: (2021)

Higher concordance of PD‐L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma
por: Mansour, Mohammed S. I., et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology
por: Hjerpe, Anders, et al.
Publicado: (2022)

Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
por: Darai-Ramqvist, Eva, et al.
Publicado: (2013)

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
por: Mundt, Filip, et al.
Publicado: (2014)

Case report: Steroid responsive mesothelioma-related pleural effusion
por: Shehata, Mena, et al.
Publicado: (2018)

Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in Mesothelioma Cells
por: Kumar-Singh, Ashish, et al.
Publicado: (2020)

Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1
por: Szatmári, Tünde, et al.
Publicado: (2017)

Management of Pleural Effusion Secondary to Malignant Mesothelioma
por: Musso, Valeria, et al.
Publicado: (2021)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
por: Takeuchi, Eiji, et al.
Publicado: (2020)

A case of pleural mesothelioma with effusive-constrictive pericarditis.
por: Weir, N. A., et al.
Publicado: (2001)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
por: Javadi, Joman, et al.
Publicado: (2021)

Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma Cells
por: Szatmári, Tünde, et al.
Publicado: (2012)

Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines
por: Ötvös, Rita, et al.
Publicado: (2011)

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
por: Dick, I.M., et al.
Publicado: (2022)

Recurrent Pericardial and Pleural Effusion due to Pericardial Pleomorphic Mesothelioma
por: Segura-Méndez, Bárbara, et al.
Publicado: (2022)

Malignant pleural mesothelioma presenting with remitting–relapsing pleural effusions: report of two cases
por: Muruganandan, Sanjeevan, et al.
Publicado: (2018)

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
por: Røe, Oluf Dimitri, et al.
Publicado: (2012)

Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
por: Nilsonne, Gustav, et al.
Publicado: (2009)

A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion
por: Gu, Rumeng, et al.
Publicado: (2021)

Gelatinous Pleural Effusion: A Diagnostic Challenge for Pleural Mesothelioma in an 80-Year-Old Man
por: Ibnian, Ali M., et al.
Publicado: (2023)

MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion
por: Ak, Guntulu, et al.
Publicado: (2015)

Pleural tuberculosis mimicking malignant mesothelioma
por: Dawood, Wajahat, et al.
Publicado: (2019)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study
por: Moretti, Gabriele, et al.
Publicado: (2021)

Identification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics
por: Palstrøm, Nicolai B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bqg2a6rhrld1r0i8289arot71l